Kane Biotech Inc. is a biotechnology company specializing in the research, development, and commercialization of innovative solutions targeting microbial biofilms. Biofilms—protective communities of microorganisms—are implicated in approximately 80% of all human and animal bacterial infections, rendering conventional antibiotics and disinfectants less effective. Kane Biotech addresses this critical healthcare challenge by developing products that disrupt, prevent, and remove biofilms from living tissues and surfaces. The company's portfolio encompasses a range of therapeutic areas, including wound care, dermatology, and animal health, with flagship offerings such as the revyve™ Antimicrobial Wound Gel for chronic wound management and the bluestem™ oral care line for pets, all leveraging their proprietary biofilm-destabilizing technologies like coactiv+™ and DispersinB®. With over 80 patents and patents pending, Kane Biotech operates as a sector leader in antimicrobial and antibiofilm technologies, serving both human and veterinary markets. Its commercialization strategy centers on licensing its technologies to global industry partners, aiming to advance patient outcomes and address the growing burden of antimicrobial resistance worldwide.